Project Grant R21AI202343
Award Date 8/5/26
Completion Date 7/31/28
Dollars Obligated $328K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Chapel Hill, NC 27599, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $233,250 on June 12, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate host-microbe interactions that drive pro-fibrotic macrophage phenotypes in inflammatory bowel disease. The research focuses on defining how adherent-invasive Escherichia coli (AIEC) and other intracellular bacteria manipulate human macrophage signaling and phenotype. The...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 17, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for research into phage-mediated reprogramming of the gut microbiome to suppress chronic inflammation in inflammatory bowel disease. The funded research, R21AI197116, engineers self-complementary non-replicative phage vectors to deliver therapeutic genetic modifications to existing...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $493,889 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate mechanisms of food-specific antibody induction in the gut. The research will elucidate how invariant natural killer T cells, type 2 conventional dendritic cells, and T follicular helper cells work in concert to promote production of food-specific immunoglobulin E antibodies, using a mouse model...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $755,684 on August 24, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop adjuvanted peptide-displaying virus-like particles (VLPs) for treating IgE-mediated peanut allergy. The research builds on a prior NIAID-funded R21 award and targets the development of a long-lasting immunomodulatory therapy for peanut allergy that does not require daily...
- The National Institute of Allergy and Infectious Diseases awarded the University of North Carolina at Chapel Hill $427,625 on April 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855). The recipient will evaluate the efficacy of coreceptor therapy using low-dose nondepleting anti-CD4 antibodies to induce de-differentiation of autoreactive T follicular helper cells (TFH) and promote their conversion into functional regulatory T cells (TREG) in the context of type 1...
- The National Institute of Allergy and Infectious Diseases awarded Regents of the University of Michigan $746,017 on April 23, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of common myeloid progenitor-derived IL-9 in gastrointestinal mast cell density and food allergy susceptibility. The research addresses a gap in understanding the cellular origin of IL-9 and the signaling pathways that drive gastrointestinal mast cell expansion and...
- The National Institute of Allergy and Infectious Diseases awarded Duke University $684,405 on July 22, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop mucosal immunotherapies targeting recurrent urinary tract infections and inflammatory bowel disease. The funded research advances immunomodulation via self-assembled peptides (ISAP), a platform using modular supramolecular polypeptide nanomaterials designed to elicit neutralizing antibody responses against...
- The National Institute of Allergy and Infectious Diseases awarded the University of Maryland, Baltimore $466,500 on February 1, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the relationship between gut microbial protein metabolism and oral immunotherapy efficacy in food allergy treatment. The award funds three linked investigations examining whether interindividual response to peanut oral immunotherapy (POIT) associates with gut microbial...
- The National Institute of Allergy and Infectious Diseases awarded Northwestern University $106,922 on February 26, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to investigate the role of cysteinyl leukotrienes in mediating food allergen absorption across the gut barrier and anaphylaxis risk. The research identifies specific cysteinyl leukotriene signaling pathways and cellular producers relevant to food allergen uptake. Prior work by the recipient demonstrated...
- The National Institute of Allergy and Infectious Diseases awarded a $1.625 million Cooperative Agreement to The University of Chicago on June 9, 2026, under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct a nested case-control study of food allergy, atopic dermatitis, and wheezing illness in early childhood using cross-tissue multi-omic analysis. The recipient will characterize transcriptional and methylome signatures in blood cells and nasal mucosal cells collected...